Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 8, Issue 1, 2016, Pages

  Cummings, Jeffrey L ^a   Zhong, Kate ^a   Kinney, Jefferson W ^b   Heaney, Chelcie ^b   Moll Tudla, Joanne ^a   Joshi, Abhinay ^c   Pontecorvo, Michael ^c   Devous, Michael ^c   Tang, Anne ^d   Bena, James ^d  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^b UNIVERSITY OF NEVADA   (United States)

^c AVID RADIOPHARMACEUTICALS   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Amyloid; ApoE genotype; Bexarotene; Clinical trial; MRI; PET

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BEXAROTENE; PLACEBO; TRIACYLGLYCEROL; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; RETINOID X RECEPTOR; TETRALIN DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; BLISTER; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DELUSION; DIVERTICULITIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG RESPONSE; FEMALE; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; AGONISTS; BLOOD; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME;

EID: 84956952788     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-016-0173-2     Document Type: Article

References (43)

1. James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA. Contribution of Alzheimer disease to mortality in the United States. Neurology. 2014;82:1045-50.
2. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013;368:1326-34.
3. Association A's. 2015 Alzheimer's disease facts and figures. Alzheimers Dement. 2015;11:332-84.
4. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37.
5. Bohm C, Chen F, Sevalle J, Qamar S, Dodd R, Li Y, et al. Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways. Mol Cell Neurosci. 2015;66:3-11.
6. Chiang K, Koo EH. Emerging therapeutics for Alzheimer's disease. Annu Rev Pharmacol Toxicol. 2014;54:381-405.
7. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-3.
8. Huang Y. Aβ-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol Med. 2010;16:287-94.
9. Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72:1487-94.
10. Peuralinna T, Tanskanen M, Mäkelä M, Polvikoski T, Paetau A, Kalimo H, et al. APOE and AβPP gene variation in cortical and cerebrovascular amyloid-β pathology and Alzheimer's disease: a population-based analysis. J Alzheimers Dis. 2011;26:377-85.
11. Koldamova R, Fitz NF, Lefterov I. ATP-binding cassette transporter A1: from metabolism to neurodegeneration. Neurobiol Dis. 2014;72:13-21.
12. Tai LM, Koster KP, Luo J, Lee SH, Wang YT, Collins NC, et al. Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J Biol Chem. 2014;289:30538-55.
13. Zhao J, Fu Y, Liu CC, Shinohara M, Nielsen HM, Dong Q, et al. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway. J Biol Chem. 2014;289:11282-92.
14. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science. 2012;335:1503-6.
15. Balducci C, Paladini A, Micotti E, Tolomeo D, La Vitola P, Grigoli E, et al. The continuing failure of bexarotene in Alzheimer's disease mice. J Alzheimers Dis. 2015;46:471-82.
16. Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, et al. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science. 2013;340:924.
17. Fitz NF, Cronican AA, Lefterov I, Koldamova R. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science. 2013;340:924.
18. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, et al. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science. 2013;340:924.
19. Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, et al. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science. 2013;340:924.
20. Farol LT, Hymes KB. Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004;4:180-8.
21. Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer's disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013;35:1-22.
22. Graeppi-Dulac J, Vlaeminck-Guillem V, Perier-Muzet M, Dalle S, Orgiazzi J. Endocrine side-effects of anti-cancer drugs: the impact of retinoids on the thyroid axis. Eur J Endocrinol. 2014;170:R253-62.
23. LaFerla FM. Preclinical success against Alzheimer's disease with an old drug. N Engl J Med. 2012;367:570-2.
24. Lowenthal J, Hull SC, Pearson SD. The ethics of early evidence - preparing for a possible breakthrough in Alzheimer's disease. N Engl J Med. 2012;367:488-90.
25. Strittmatter WJ. Old drug, new hope for Alzheimer's disease. Science. 2012;335:1447-8.v
26. de Vries-van der Weij J, de Haan W, Hu L, Kuif M, Oei HL, van der Hoorn JW, et al. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology. 2009;150:2368-75.
27. Pierrot N, Lhommel R, Quenon L, Hanseeuw B, Dricot L, Sindic C, et al. Targretin improves cognitive and biological markers in a patient with Alzheimer's disease. J Alzheimers Dis. 2015;49:271-6.
28. Cummings JL. Optimizing phase II of drug development for disease-modifying compounds. Alzheimers Dement. 2008;4:S15-20.
29. Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement. 2011;7:e13-44.
30. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13:419-31.
31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-44.
32. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
33. Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power to characterize longitudinal amyloid-β PET changes and evaluate amyloid-modifying treatments using a cerebral white matter reference region. J Nucl Med. 2015;56:560-6.
34. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-64.
35. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-4.
36. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-14.
37. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11:S33-9.
38. Calero O, Hortiguela R, Bullido MJ, Calero M. Apolipoprotein E genotyping method by real time PCR, a fast and cost-effective alternative to the TaqMan and FRET assays. J Neurosci Methods. 2009;183:238-40.
39. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA. 2011;305:275-83.
40. 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56:567-74.
41. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614-29.
42. Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, et al. APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012;287:41774-86.
43. Michaelson DM. APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease. Alzheimers Dement. 2014;10:861-8.